Clinical Trial Update: Forxiga CKD Japan Post-Marketing Surveillance (PMS)

View source ↗

Summary

AstraZeneca reports the completion of the post-marketing surveillance study of dapagliflozin (Forxiga) for chronic kidney disease in Japan.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Kidney Disease

Drugs mentioned

• Forxiga (dapagliflozin)

Snippet

Sponsor: AstraZeneca | Conditions: Chronic Kidney Disease | Status: COMPLETED